The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy

COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy

March 18, 2021 • By Joseph Cantrell, JD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Despite the challenging policy environment created by the COVID-19 pandemic, the ACR has consistently engaged with policymakers to ensure the voice of rheumatology is heard when important decisions are being made that impact practices and patients. Throughout the pandemic, the ACR has engaged with federal, regulatory and state leaders on many issues, such as patient access to hydroxychloroquine, state licensing issues with telemedicine and emergency funding to sustain practices. Advocacy efforts are continuing with our latest outreach to state leaders to ensure that patients on immunosuppressants have access to COVID-19 vaccination.

You Might Also Like
  • Coronavirus Vaccination Assistance
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy
  • Guidance Coming for Anticipated COVID-19 Vaccine
Also By This Author
  • 2020 State Legislative Roundup: The Year That Could Have Been & the Year That Was

Late last year, as COVID-19 vaccines began to enter the marketplace, the ACR recognized that providers and patients would need vaccine guidance. The COVID-19 Vaccine Clinical Guidance Task Force was created with the goal of developing guidance and recommendations for rheumatology patients. This kind of guidance generally takes quite some time to develop, but the task force expedited the process and completed the guidance on a compressed timeline, with approval by the Board of Directors on Feb. 8. The guidance recognized that patients on immunosuppressants have increased vulnerability to COVID-19 infection. The advocacy implications of this guidance became clear: These patients are at increased risk of adverse outcomes and need priority access to vaccinations.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR’s Committee on Rheumatologic Care (CORC) recognized an opportunity for engaging policymakers to ensure that the ACR’s guidance was reflected in state policy. With the vaccination guidance as a framework, CORC worked with the ACR’s Government Affairs Committee and the Affiliate Society Council to draft letters to state policymakers making the case that immunosuppressed patients should be given priority access to COVID-19 vaccinations. As plans for the outreach effort coalesced, research revealed that four states had already opened vaccinations to immunosuppressed patients. That left 46 states to target for outreach. The ACR, working with state and local rheumatology societies, sent letters to the governors, lieutenant governors and insurance commissioners of all of the target states to advocate for patients who are on immunosuppressant treatment to have early access to COVID-19 vaccines. It was a massive undertaking that drew on a roadmap developed during the ACR’s outreach on hydroxychloroquine shortages.

Coordinated Efforts
In the weeks following the publication of the ACR guidance and state outreach efforts, many states opened vaccinations to immunosuppressed patients. Many more are planning to follow suit over the coming weeks. Some states are also considering a further step of expanding vaccine eligibility to the broader population of patients with autoimmune and inflammatory rheumatic diseases,  a group at higher risk for hospitalization and worse outcomes with COVID-19 compared to the general population. It would be easy to stop now, proclaim victory and move on to the next challenge, but it is important to highlight the process that led to this success.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This effort involved multiple ACR departments and committees and built on a long history of working with internal and external partners, including state and local rheumatology societies. The connections between different ACR priorities, such as clinical guidance and advocacy, may not always be immediately clear. But the effort to improve COVID-19 vaccination of rheumatology patients, from the development of clinical guidance though state outreach to get those patients access to vaccines, has been a shining example of the great strength of ACR advocacy.

One of the most effective parts of rheumatology’s advocacy capacity comes from the ability to translate the work of the ACR into strong, actionable public policy recommendations, then amplify those messages through member engagement. ACR/ARP members sent over 500 messages to state leaders supporting the ACR’s position on vaccinations. Additionally, our volunteer leaders and staff put in countless hours, often on evenings and weekends, to execute every phase of this strategy, from the formulation of the clinical guidance to the final media outreach. It took many different parts of the ACR working together to achieve this win for the patients that our members treat. It is, however, an important reminder of how strong and effective this organization and the rheumatology community can be when working toward a common goal. After more than a year of living in this pandemic, patients are one step closer to resuming a normal life because of the work of the ACR and its members. That is truly an accomplishment to celebrate.


Joseph Cantrell, JD, is the senior manager of state affairs for the ACR.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: American College of Rheumatology, Legislation & Advocacy Tagged With: ACR advocacy, COVID-19, state society, vaccination

You Might Also Like:
  • Coronavirus Vaccination Assistance
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy
  • Guidance Coming for Anticipated COVID-19 Vaccine
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.